Send to

Choose Destination
Thorax. 2018 Apr;73(4):391-392. doi: 10.1136/thoraxjnl-2017-210035. Epub 2017 Sep 7.

Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis.

Author information

Interstitial Lung Diseases Program, Federal University of São Paulo, São Paulo, Brazil.


The predictive value of the decline in FVC by ≥10% on survival in patients with fibrotic hypersensitivity pneumonitis is unknown. Of 112 patients included, 66 (59%) had surgical lung biopsies. Patients with ≥10% decline in predicted FVC after 6-12 months had a significantly increased risk of all-cause mortality (median survival 53 months, 95% CI 37 to 69 vs 139 months, 95% CI 66 to 212 months, p=0.007). On multivariate analysis remained associated with increasing mortality: decline in FVC by ≥10% (HR 4.13, 95% CI 1.96 to 8.70, p=0.005), lower FVC% (HR 1.03, 95% CI 1.01 to 1.05, p=0.003) and with decreasing mortality improvement with antigen avoidance (HR 0.18, 95% CI 0.04 to 0.77, p=0.021).


hypersensitivity pneumonitis

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center